Wegovy's Heart-Health Edge: A Game Changer in Weight-Loss Drugs
Published on: Aug. 31, 2025, 10:01 p.m. | Source: Devdiscourse
Novo Nordisk's weight-loss drug Wegovy has shown a 57% reduction in heart attack, stroke, or death risk compared to Eli Lilly's drugs in real-world studies. While not a randomized trial, these findings highlight Wegovy's significant cardiovascular benefits despite increased competition in the weight-loss drug market.
